Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-005102
Filing Date
2021-02-05
Accepted
2021-02-05 18:51:12
Documents
1
Period of Report
2021-02-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4039
  Complete submission text file 0000899243-21-005102.txt   5541
Mailing Address 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116
Business Address 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Issuer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CEREVEL THERAPEUTICS, INC. 51 ASHTOR PLACE NEW YORK NY 10003
Business Address
Renger John (Reporting) CIK: 0001830363 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39311 | Film No.: 21597835